Ultra-widefield retinal imaging tech company Optos announced the dual milestone of installing 25,000 devices worldwide and the collection of 2,500 peer-reviewed studies spanning 235 disease states.
"This remarkable double milestone reflects the unwavering commitment that Optos has had to innovation and excellence in providing the best and clinically relevant technology available, since our inception,” said Optos CEO Robert Kennedy.
With a total of nine imaging modalities available across all Optos device platforms – including the recent addition of Optomap Color RGB, natural colour and Optomap blue fundus autofluorescence imaging modalities – Optos keeps expanding its technology offering, said Kennedy. “In addition, the combined imaging devices integrate ultra-widefield retinal imaging with Optomap-guided OCT, providing clinicians with comprehensive insights into retinal health.”
